2 α-(3-hydroxypropyl)- and 2 α-(3-hydroxypropoxy)-1 α,25-dihydroxyvitamin D3 accessible to vitamin D receptor mutant related to hereditary vitamin D-resistant rickets

Chemical and Pharmaceutical Bulletin

Volumn 51, Issue 3, 2003, Pages 357-358

  Kittaka, Atsushi ^a   Kurihara, Masaaki ^b   Peleg, Sara ^c   Suhara, Yoshitomo ^a,d   Takayama, Hiroaki ^a  

^a TEIKYO UNIVERSITY   (Japan)

^b NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d KOBE PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

2 substituted 1 ,25 dihydroxyvitamin D3; Docking study; Mutant vitamin D receptor; Potent ligand; Rickets

Indexed keywords

2ALPHA (3 HYDROXYPROPOXY) 1ALPHA,25 DIHYDROXYVITAMIN D3; 2ALPHA (3 HYDROXYPROPYL) 1ALPHA,25 DIHYDROXYVITAMIN D3; COLECALCIFEROL DERIVATIVE; HORMONE; HYDROGEN; HYDROXYL GROUP; UNCLASSIFIED DRUG; VITAMIN D RECEPTOR; CALCITRIOL RECEPTOR; DIHYDROXY VITAMIN D3; DIHYDROXY-VITAMIN D3; DRUG DERIVATIVE; VITAMIN D;

ARTICLE; DRUG RECEPTOR BINDING; GENE MUTATION; HYDROGEN BOND; STRUCTURE ANALYSIS; VITAMIN D RESISTANT RICKETS; CHEMISTRY; GENETICS; HYPOPHOSPHATEMIA; METABOLISM; MUTATION; VITAMIN D DEFICIENCY;

HYDROGEN BONDING; HYPOPHOSPHATEMIA, FAMILIAL; MUTATION; RECEPTORS, CALCITRIOL; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 0042398448     PISSN: 00092363     EISSN: 13475223     Source Type: Journal    
DOI: 10.1248/cpb.51.357     Document Type: Article

References (13)

1. Umezono K., Murakami K. K., Thompson C. C., Evans R. M., Cell, 65, 1255-1266 (1991).
2. Evans R. M., Science, 240, 889-895 (1988).
3. Yanagisawa J., Yanagi Y., Masuhiro Y., Suzawa M., Watanabe M., Kashiwagi K., Toriyabe T., Kawabata M., Miyazono K., Kato S., Science, 283, 1317-1321 (1999).
4. Malloy P. J., Pike J. W., Feldman D., Endocr. Rev., 20, 156-188 (1999).
5. Rochel N., Wultz J. M., Mitschler A., Klaholz B., Moras D., Mol. Cell, 5, 173-179 (2000).
6. Gardezi S. A., Nguyen C., Malloy P. J., Posner G. H., Feldman D., Peleg S., J. Biol. Chem., 276, 29148-29156 (2001).
7. Swann S. L., Bergh J. J., Farach-Carson M. C., Koh J. T., Org. Lett., 4, 3863-3866 (2002).
8. Swann S. L., Bergh J., Farach-Carson M. C., Ocasio C. A., Koh J. T., J. Am. Chem. Soc., 124, 13795-13805 (2002).
9. 3, in protease assay, interaction with coactivator, as in vitro assay, and transcriptional activity as functional assay.
10. Suhara Y., Nihei K., Kurihara M., Kittaka A., Yamaguchi K., Fujishima T., Konno K., Miyata N., Takayama H., J. Org. Chem., 66, 8760-8771 (2001).
11. Kittaka A., Suhara Y., Takayanagi H., Fujishima T., Kurihara M., Takayama H., Org. Lett., 2, 2619-2622 (2000).
12. Modeled structures were constructed by molecular dynamics simulation and molecular mechanics energy minimization. 32 amino acid residues were used for calculation. All calculations were performed by MacroModel ver. 6.5.
13. Peleg S., Nguyen C., Woodard B. T., Lee J. K., Posner G. H., Mol. Endocrinol., 12, 525-535 (1998).